ABIO ARCA biopharma Inc
18,317
$4.00
$0.28
(7.53%)
| Watchers | 18,317 |
| 52-Wk Low | $1.56 |
| 52-Wk High | $4.00 |
| Market Cap | $58.03M |
| Volume | 532.00 |
| 52-Wk High | $4.00 |
| 52-Wk Low | $1.56 |
ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIOBusiness Wire • 6 days ago
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of ARCA biopharma, Inc. (the Company) (NasdaqCM...
Share to Feed
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO PR Newswire NEW YORK, April 10, 2024 NEW...
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA...
StockNews.com assumed coverage on shares of ARCA biopharma (NASDAQ:ABIO - Free Report) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company's stock...
Equities research analysts at StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO - Get Free Report) in a note issued to investors on Thursday. The firm set a "sell" rating on the...
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm PR Newswire NEW YORK, April 5, 2024 NEW YORK...
ARCA Biopharma stock drops on CEO departure...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO PR Newswire NEW YORK, April 4, 2024 NEW...
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company...